Pfizer

Oncology Research and Development Postdoctoral Program

Brion W. Murray, Ph.D.
Research Fellow
Senior Editor, Molecular Cancer Therapeutics
Associate Editor, Frontiers in Pharmacology
Member, Faculty of 1000

Education

Undergrad: B.S. Chemistry, University of North Carolina at Chapel Hill
Graduate: Ph.D. Biochemistry, University of Maryland at College Park
Postdoctoral training: The Scripps Research Institute, La Jolla

Research Interests:

My laboratory studies oncogenic signaling and mechanisms of drug resistance.  We primarily focus on the regulation of protein kinases.

Selected Publications

Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He Y, Yu X, Nagata A, VanArsdale T and Murray BW. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Mol Cancer Ther; 15(10); 2273–81 (2016)

Schwab RB, Koehler M, Ali SM and Murray BW. Genomic profiling and treatment of HER2+, ER+, PgR+ “triple positive” breast cancer: A case report and literature review. Cancer Treatment and Research Communications 9:27–31 (2016)

Pemovska P, Johnson, P, Kontro M, Repasky, GA, Chen J, Wells P, Cronin CN, McTigue M, Kallioniemi O, Porkka K, Murray BW and Wennerberg K. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature, 518, 102–105 (2015).

Schwartz PA, Kuzmic P, Solowiej J, Bergqvist S, Bolanos B, Almaden C, Nagata A, Ryan K, Feng J, Dalvie D, Kath JC, Xu M, Wani R and Murray BW. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. PNAS 111(1):173-8 (2014).